Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 12 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 10420748

    Methods of treatment associated with the granulocyte colony-stimulating factor receptor

    Ligand Pharmaceuticals Incorporated · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  2. US 10421798

    Factor VIII compositions and methods of making and using same

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  3. US 10415044

    Adeno-associated virus vectors encoding modified G6PC and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  4. US 10400225

    TAL effector-mediated DNA modification

    Regents of the University of Minnesota · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  5. US 10391157

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  6. US 10392434

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  7. US 10391152

    Methods of using a fixed dose of a clotting factor

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  8. US 10376495

    Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)

    The United States Government as Represented by the Department of Veterans · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted

  9. US 10370679

    Modified immunization vectors

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  10. US 10369192

    Methods and compositions for delivery of exogenous factors to nervous system sites

    REGENERATIVE RESEARCH FOUNDATION · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  11. US 10370348

    Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  12. US 10370430

    Recombinant factor VIII proteins

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  13. US 10370680

    Method of treating factor IX deficiency using nuclease-mediated targeted integration

    Sangamo Therapeutics, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  14. US 10322118

    Compounds and methods for inhibiting Cif virulence factor

    THE REGENTS OF TE UNIVERSITY OF CALIFORNIA · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted

  15. US 10308941

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  16. US 10294483

    Eimeria tenella elongation factor-1 alpha recombinant immunogenic compositions which induce active protective immunity against avian coccidiosis

    The United States of America, as represented by the Secretary of Agriculture · Granted May 21, 2019 · Expires May 16, 2039

    granted

  17. US 10280423

    Compositions and methods for modulating complement factor B expression

    Ionis Pharmaceuticals, Inc. · Granted May 7, 2019 · Expires May 2, 2039

    granted

  18. US 10272163

    Factor VIII mutation repair and tolerance induction

    THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  19. US 10273274

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  20. US 10273228

    Hepatitis B viral assembly effectors

    ASSEMBLY BIOSCIENCES, INC. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  21. US 10265405

    Polymers for delivery of factor VIII and/or factor IX

    The Board of Regents of the University of Texas System · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  22. US 10246463

    Hypoxia-inducible factor 1 (HIF-1) inhibitors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  23. US 10221455

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  24. US 10221243

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.